Skip to main content

Advertisement

Table 2 Percentage mean cytotoxicities of DNA-acting drugs and their combinations with Nar on human colorectal and breast cancer cells

From: Growth inhibitory and chemo-sensitization effects of naringenin, a natural flavanone purified from Thymus vulgaris, on human breast and colorectal cancer

Treatment with DNA-acting drugs and their combinations with Nar Percentage mean cytotoxicity a Fold increase in therapeutic efficacy
SW837 HTB132 SW837 b HTB132 c
5 FU (1 × 10−10 - 1 × 10−3 M) 8 ± 1.0 54 ± 0.42   
5 FU (1 × 10−10 - 1 × 10−3 M) + Nar (0.5 mM) 50 ± 1.6 96 ± 0.44 6.25 1.7
CIP (1 × 10−10 - 1 × 10−3 M) 3 ± 0.8 49 ± 0.5   
CIP (1 × 10−10 - 1 × 10−3 M) + Nar (0.5 mM) 39 ± 2 80 ± 0.6 13 1.63
CAP (1 × 10−10 - 1 × 10−3 M) 9 ± 2 40 ± 2   
CAP (1 × 10−10 - 1 × 10−3 M) + Nar (0.5 mM) 27 ± 1.0 83 ± 1.5 3 2.1
CPT (1 × 10−10 - 1 × 10−3 M) 8 ± 1.1 60 ± 2.2   
CPT (1 × 10−10 - 1 × 10−3 M) + Nar (0.5 mM) 50 ± 2.6 95 ± 0.3 6.25 1.58
DOX (1 × 10−10 - 1 × 10−3 M) 6 ± 1.3 54 ± 1.3   
DOX (1 × 10−10 - 1 × 10−3 M) + Nar (0.5 mM) 41 ± 3 84 ± 0.6 6.83 1.56
CPA (1 × 10−11 - 1 × 10−4 M) 15 ± 2.6 44 ± 0.8   
CPA (1 × 10-11 - 1 × 10-4 M) + Nar (0.5 mM) 47 ± 1.1 88 ± 1 3.13 2
ETP (1 × 10−10 - 1 × 10−3 M) 10 ± 2 51 ± 1.6   
ETP (1 × 10−10 - 1 × 10−3 M) + Nar (0.5 mM) 57 ± 0.6 83 ± 0.93 5.7 1.63
ELP (1 × 10−11 - 1 × 10−4 M) 23 ± 2.5 51 ± 1.6   
ELP (1 × 10−11 - 1 × 10−4 M) + Nar (0.5 mM) 70 ± 1.8 93 ± 0.6 3.04 1.82
  1. aThe data are based on the mean of absorbance from 3 independent experiments.
  2. b,c P-values of the combined treatments with DNA-acting drugs and Nar versus DNA-acting drugs = 0.0001.